Adial Pharmaceuticals (ADIL) Cash from Financing Activities (2017 - 2026)
Adial Pharmaceuticals (ADIL) posted Cash from Financing Activities of $315284.0 for Q1 2026, down 94.63% sequentially from $5.9 million in Q3 2025, and up 522.5% YoY from $50648.0 in Q1 2025.
Adial Pharmaceuticals (ADIL) Cash from Financing Activities (2017 - 2026) Analysis & Trends
Adial Pharmaceuticals has reported Cash from Financing Activities for 10 years, with the latest figure at $315284.0 in Q1 2026.
- Quarterly Cash from Financing Activities rose 522.5% year-over-year to $315284.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.5 million (down 4.89% YoY) and the FY2025 annual result came in at $8.5 million, up 8.0% from the prior year.
- Cash from Financing Activities eased to $315284.0 in Q1 2026 per ADIL's latest filing, from $5.9 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $9.1 million in Q1 2022 and troughed at $58.0 in Q2 2023.
- A 5-year average of $2.8 million and a median of $609613.0 in 2023 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities plunged 99.93% in 2022, then soared 708677.59% in 2024.
- Over 5 years, Cash from Financing Activities stood at $1865.0 in 2022, then jumped by 181334.69% to $3.4 million in 2023, then soared by 131.87% to $7.8 million in 2024, then decreased by 25.13% to $5.9 million in 2025, then plunged by 94.63% to $315284.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $315284.0, $5.9 million, and $5.3 million for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Adial Pharmaceuticals | 29.02 Mn | 29.02 Mn | - | 25.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 315,284.00 |
| Mar 31, 2026 | 315,284.00 |
| Sep 30, 2025 | 5.87 Mn |
| Sep 30, 2025 | 5.87 Mn |
| Jun 30, 2025 | 5.30 Mn |
| Jun 30, 2025 | 5.30 Mn |
| Mar 31, 2025 | 50,648.00 |
| Mar 31, 2025 | 50,648.00 |
| Sep 30, 2024 | 7.85 Mn |
| Sep 30, 2024 | 7.85 Mn |
| Jun 30, 2024 | 411,091.00 |
| Jun 30, 2024 | 411,091.00 |
| Mar 31, 2024 | 3.82 Mn |
| Mar 31, 2024 | 3.82 Mn |
| Dec 31, 2023 | 3.38 Mn |
| Dec 31, 2023 | 3.38 Mn |
| Sep 30, 2023 | 138,669.00 |
| Sep 30, 2023 | 138,669.00 |
| Jun 30, 2023 | 58.00 |
| Jun 30, 2023 | 58.00 |